Update on COVID-19 (22 March 2020)

Dear all,

The COVID-19 pandemic continues to spread, and in our commitment to provide transparency to our stakeholders, I want to share an update on our clinical trials.

It was decided to pause enrollment into the filgotinib trials in order to help protect patient safety. This includes the Phase 2 and Phase 3 trials of filgotinib in Crohn’s disease (DIVERSITY), the Phase 3 in psoriatic arthritis (PENGUIN), the Phase 2 trial in uveitis, and the MANTA and MANTA-RAy trials. 

We anticipate the Phase 3 program in ankylosing spondylitis will now start later this year. 

This does not impact the Phase 3 SELECTION program in ulcerative colitis, as this study is fully enrolled, and we still expect results in the second quarter of this year. 

I want to assure you that the Galapagos team continues to face this unprecedented situation with resilience. And as challenging as the COVID-19 crisis is, this too shall pass. Supported by a strong balance sheet, I firmly believe that we can weather this storm. This also comes with a responsibility that we do not take lightly: we are more determined than ever in our unwavering ambition to bring innovation to patients worldwide.

Wishing you all the very best in these difficult times,

Onno van de Stolpe
CEO

To read more Press Release articles, click here.